Search results for "Germany"

showing 10 items of 1172 documents

Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No …

2002

BACKGROUND: To determine whether patients with high-risk metastatic breast cancer draw benefit from combination chemotherapy as first-line treatment. PATIENTS AND METHODS: A total of 260 women with measurable metastatic breast cancer fulfilling high-risk criteria, previously untreated with chemotherapy for their metastatic disease, were randomized to receive either mitoxantrone 12 mg/m(2) or the combination of fluorouracil 500 mg/m(2), epirubicin 50 mg/m(2) and cyclophosphamide 500 mg/m(2) (FEC) every 3 weeks. Treatment was continued until complete remission plus two cycles, or until disease progression. In the case of partial remission or stable disease, treatment was stopped after 12 cycl…

OncologyAdultmedicine.medical_specialtyLung NeoplasmsCyclophosphamidemedicine.medical_treatmentBone NeoplasmsBreast NeoplasmsRisk AssessmentSensitivity and SpecificityDisease-Free SurvivalStatistics NonparametricInternal medicineGermanyAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansCyclophosphamideAgedEpirubicinNeoplasm StagingProbabilityProportional Hazards ModelsChemotherapyMitoxantronePerformance statusbusiness.industryBiopsy NeedleLiver NeoplasmsCombination chemotherapyHematologyMiddle Agedmedicine.diseaseMetastatic breast cancerSurvival AnalysisSurgeryLogistic ModelsTreatment OutcomeOncologyQuality of LifeVindesineFemaleFluorouracilMitoxantronebusinessmedicine.drugEpirubicinAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Participation in cervical cancer screening in Germany.

2010

OncologyCervical cancerAdultmedicine.medical_specialtyEpidemiologybusiness.industryPublic Health Environmental and Occupational HealthUterine Cervical NeoplasmsMiddle AgedCervical cancer screeningmedicine.diseaseYoung AdultInternal medicineGermanymedicineHumansMass ScreeningFemalePatient ParticipationbusinessAgedPreventive medicine
researchProduct

Second primary cancers after cancer of unknown primary in Sweden and Germany: efficacy of the modern work-up.

2012

In unsparing efforts to find the hidden primaries, second primary cancers (SPCs) unrelated to cancer of unknown primary (CUP) are found. The detection rates of SPCs after CUP can be considered as measures for the effectiveness of modern diagnostic techniques in finding tumors. We aimed to compare the rates of specific SPCs found after the work-up of CUP and the more sign/symptom-directed diagnostic approaches applied after any other cancer. The number of CUP patients identified in the nationwide Swedish database and nine German cancer registries was 24 641 from 1997 through 2006, and rate ratios (RRs) for SPCs were recorded in two follow-up periods. The detection rate of SPCs immediately af…

OncologyMaleCancer Researchmedicine.medical_specialtyDatabases FactualEpidemiologySecond Primary CancersProstateInternal medicineGermanymedicineHumansRegistriesAgedAged 80 and overSwedenUrinary bladderLungbusiness.industryPublic Health Environmental and Occupational HealthCancerNeoplasms Second PrimaryMiddle Agedmedicine.diseaseWork-upLymphomaSurgerymedicine.anatomical_structureTreatment OutcomeOncologyCancer of unknown primaryNeoplasms Unknown PrimaryFemalebusinessFollow-Up StudiesEuropean journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
researchProduct

Survival of elderly patients with multiple myeloma-Effect of upfront autologous stem cell transplantation

2016

Abstract Background The aim of this study was to determine the value of upfront autologous transplantation (ASCT) in elderly patients (60–79 years) with myeloma. Methods We analysed relative survival (RS) of patients diagnosed in 1998–2011 and treated with ASCT within 12 months after diagnosis in Germany (n = 3591; German Registry of Stem Cell Transplantation) and compare RS with survival of myeloma patients diagnosed in the same years in Germany (n = 13,903; population-based German Cancer Registries). Results Utilisation of ASCT has increased rapidly between 2000–2002 and 2009–2011 (60–64years: 7.0–43.0%; 65–69 years: 6.6–23.7%; 70–79 years: 0.4–4.0%). Comparison of 5-year RS of patients f…

OncologyMaleCancer Researchmedicine.medical_specialtyPopulationMedizinImproved survivalTransplantation Autologous03 medical and health sciences0302 clinical medicineAutologous stem-cell transplantationInternal medicineGermanyMedicineAutologous transplantationHumanseducationMultiple myelomaAgedRetrospective Studieseducation.field_of_studyRelative survivalbusiness.industryCancerMiddle Agedmedicine.diseaseSurvival AnalysisTransplantationOncology030220 oncology & carcinogenesisFemalebusinessMultiple Myeloma030215 immunologyStem Cell Transplantation
researchProduct

Patterns of Prior and Subsequent Neoplasms in Children and Adolescents With Soft Tissue Sarcomas.

2020

Background The occurrence of prior, concurrent and subsequent neoplasms (SN) represents a serious problem in children and adolescents with soft tissue sarcomas. Pathogenic germline variants contribute to the diagnosis of multiple neoplasms in sarcoma survivors. Materials and methods The records of 748 children and adolescents, diagnosed with soft tissue sarcomas and registered in trials/registries by the cooperative soft tissue sarcoma (Cooperative Weichteilsarkom Studie) group, were reviewed for the occurrence of SNs. Reference histology review was available for all cases; the presence of oncogenic fusions known at the time of diagnosis was confirmed for fusion-positive (F+) entities. Resu…

OncologyMalemedicine.medical_specialtyAdolescentOncogene Proteins FusionGermline03 medical and health sciences0302 clinical medicineCancer SurvivorsRisk FactorsInternal medicineGermanyBiomarkers TumorMedicineHumansRegistriesNeurofibromatosisChildGerm-Line MutationClinical Trials as Topicbusiness.industryIncidence (epidemiology)Soft tissue sarcomaIncidenceSoft tissueInfantHistologyNeoplasms Second PrimarySarcomaHematologymedicine.diseasePrognosisCombined Modality TherapySurvival RateOncology030220 oncology & carcinogenesisChild PreschoolPediatrics Perinatology and Child HealthFemaleSarcomabusiness030215 immunologyFollow-Up StudiesJournal of pediatric hematology/oncology
researchProduct

Cohort study of occupational cosmic radiation dose and cancer mortality in German aircrew, 1960-2014.

2020

ObjectivesTo determine cancer mortality compared with the general population and to examine dose-response relationships between cumulative occupational radiation dose and specific cancer outcomes in the German aircrew cohort.MethodsFor a cohort of 26 846 aircrew personnel, standardised mortality ratios (SMR) were calculated. Dose-response analyses were carried out using Poisson regression to assess dose-related cancer risks for the period 1960–2014. Exposure assessment comprises recently available dose register data for all cohort members and newly estimated retrospective cabin crew doses for 1960–2003.ResultsSMR for all-cause, specific cancer groups and most individual cancers were reduced…

OncologyMalemedicine.medical_specialtyNeoplasms Radiation-InducedPopulationRadiation DosageEffective dose (radiation)Cohort Studies03 medical and health sciencessymbols.namesake0302 clinical medicineInternal medicineGermanyOccupational ExposuremedicineHumansPoisson regressioneducationMelanomaAgededucation.field_of_studyCumulative dosebusiness.industryBrain NeoplasmsPublic Health Environmental and Occupational HealthDose-Response Relationship RadiationMiddle Aged030210 environmental & occupational healthOccupational Diseases030220 oncology & carcinogenesisRelative riskCohortsymbolsAircrewFemalebusinessCosmic RadiationCohort studyOccupational and environmental medicine
researchProduct

Risk estimation for biliary tract cancer: Development and validation of a prognostic score.

2017

Background & Aims Biliary tract cancer is a rare tumour entity characterized by a poor prognosis. We aimed to identify prognostic factors and create a prognostic score to estimate survival. Methods Clinical data of the training set, consisting of 569 patients treated from 2000 to 2010 at Hannover Medical School, were analysed. A prognostic model defining three prognostic risk groups was derived from Cox regression analyses. The score was applied and validated in an independent cohort of 557 patients from four different German centres. Results Median overall survival (OS) was 14.5 months. If complete resection was performed, the patients had a significantly improved OS (23.9 months; n=242) a…

OncologyMalemedicine.medical_specialtyRisk AssessmentPrognostic scoreMetastasisCholangiocarcinomaCohort Studies03 medical and health sciences0302 clinical medicineInternal medicineGermanymedicineHumansAgedBiliary tract neoplasmBiliary tract cancerHepatologybusiness.industryProportional hazards modelMiddle Agedmedicine.diseasePrognosisSurgeryBiliary Tract Neoplasms030220 oncology & carcinogenesisCohort030211 gastroenterology & hepatologyFemaleRisk assessmentbusinessCohort studyLiver international : official journal of the International Association for the Study of the Liver
researchProduct

Relations of Metabolically Healthy and Unhealthy Obesity to Digital Vascular Function in Three Community‐Based Cohorts: A Meta‐Analysis

2017

Background Microvascular dysfunction is a marker of early vascular disease that predicts cardiovascular events. Whether metabolically healthy obese individuals have impaired microvascular function remains unclear. The aim of this study was to evaluate the relation of obesity phenotypes stratified by metabolic status to microvascular function. Methods and Results We meta‐analyzed aggregate data from 3 large cohorts (Brazilian Longitudinal Study of Adult Health, the Framingham Heart Study, and the Gutenberg Heart Study; n=16 830 participants, age range 19–90, 51.3% men). Regression slopes between cardiovascular risk factors and microvascular function, measured by peripheral arterial tonometr…

Oncologycardiovascular risk factorsMaleEpidemiology030204 cardiovascular system & hematologyOverweightCohort Studies0302 clinical medicineendothelial functionRisk FactorsGermanyVascular Disease030212 general & internal medicine2. Zero hungerSystematic Review and Meta‐AnalysisMiddle Aged3. Good healthMeta-analysisPulsatile FlowEndothelium/Vascular Type/Nitric OxideFemalemedicine.symptomCardiology and Cardiovascular MedicineBrazilCohort studyAdultmedicine.medical_specialtyManometrybody mass indexmetabolic syndromeFingers03 medical and health sciencesInternal medicinemedicineHumansObesityAgedObesity Metabolically BenignVascular diseasebusiness.industryCase-control studyOverweightmedicine.diseaseObesityUnited StatesEndocrinologyCase-Control StudiesMicrovesselsEndothelium VascularMetabolic syndromebusinessBody mass indexJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
researchProduct

Lipoprotein(a) – Marker for cardiovascular risk and target for lipoprotein apheresis

2019

Lipoprotein(a) (Lp(a)) consists of an LDL particle whose apolipoprotein B (apoB) is covalently bound to apolipoprotein(a) (apo[a]). An increased Lp(a) concentration is a causal, independent risk factor for atherosclerotic cardiovascular disease (ASCVD) and a predictor of incident or recurrent cardiovascular events. Although Lp(a) was first described as early as 1963, only the more recent results of epidemiological, molecular, and genetic studies have led to this unequivocal conclusion. More than 20% of Western populations have elevated Lp(a) values. Lp(a) concentrations should be always part of the lipid profile when ASCVD risk is assessed. However, presence of other risk factors, laborator…

Oncologymedicine.medical_specialtyApolipoprotein B030204 cardiovascular system & hematologyRisk Assessment03 medical and health scienceschemistry.chemical_compound0302 clinical medicineGermanyInternal medicineInternal MedicineHumansMedicineMedical history030212 general & internal medicineFamily historyRisk factorbiologymedicine.diagnostic_testbusiness.industryCholesterolPatient SelectionGeneral MedicineLipoprotein(a)AtherosclerosischemistryCardiovascular DiseasesBlood Component Removalbiology.proteinlipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicinebusinessLipid profileBiomarkersLipoprotein(a)LipoproteinAtherosclerosis Supplements
researchProduct

Tumor biology in older breast cancer patients – What is the impact on survival stratified for guideline adherence? A retrospective multi-centre cohor…

2015

Abstract Purpose The tumor biology of older breast cancer patients (oBCP) is usually less aggressive, however applied adjuvant treatment is often less potent resulting in an impaired disease free survival and overall survival in this group. This study tries to answer the following questions for the biological subtypes of oBCP (70+ y): (1) Is there a significant difference in the distribution of the biological subtypes of oBCP vs younger breast cancer patients (yBCP; 50–69 y)? (2) Which biological subtype has the highest rate of non-guideline-adherent-treatment (GL−) among oBCP? (3) Is a single GL− (i.e. radiotherapy/surgery/endocrine-therapy/chemotherapy) significantly associated with the s…

Oncologymedicine.medical_specialtyReceptor ErbB-2medicine.medical_treatmentBreast NeoplasmsBreast cancerGermanyInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAgedRetrospective StudiesChemotherapybusiness.industryTumor biologyGeneral MedicineGuidelineMiddle Agedmedicine.diseaseSurvival AnalysisRadiation therapyTreatment OutcomeChemotherapy AdjuvantHormone receptorFemaleSurgeryGuideline AdherenceHealth Impact AssessmentNeoplasm Recurrence LocalbusinessAdjuvantCohort studyThe Breast
researchProduct